EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Ingrid G Rekeland iD, Kari Sørland, Lisbeth Lykke Neteland, Alexander Fosså, Kine Alme, Kristin Risa, Olav Dahl, Karl J Tronstad, Olav Mella, Øystein Fluge

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307484 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Ingrid G Rekeland und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Rituximab, Cyclophosphamide, Fatigue Syndrome, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Forskningsråd, Helse Vest, MEandYou Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In this six-year follow-up study, we used patient-reported outcome measures (PROMs) to compare values at baseline, at 18 months, and at six-year follow up from the CycloME and the RituxME trials.

Methods

Based on the hypothesis that ME/CFS in a subgroup of patients is a variant of an autoimmune disease, we performed two clinical trials between 2014 and 2017. The RituxME trial was a randomized, double-blind and placebo-controlled phase III trial of 151 patients, assessing the B-cell depleting antibody rituximab. The CycloME trial was an open-label phase II trial of 40 patients using intravenous cyclophosphamide. Here we report six-year follow-up from both trials, using the Short Form 36 Physical Function (SF-36 PF) and DePaul short form (DSQ-SF) questionnaires.

Result

Of the patients available after six years, 75.7% of RituxME and 94.4% of CycloME patients participated. In the RituxME rituximab group, the mean SF-36 PF scores were 32.9 at baseline, 42.4 at 18 months and 45.5 at six years. In the placebo group, the mean SF-36 PF scores were 32.3 at baseline, 45.5 at 18 months and 43.1 at six years. In the CycloME trial, mean SF-36 PF increased from 35.4 at baseline to 54.4 at 18 months, and 56.7 at six years. At six-year follow-up, 44.1% of cyclophosphamide-, 27.6% of rituximab- and 20.4% of placebo-treated patients had an SF-36 PF ≥ 70, and further, 17.6%, 8.6% and 7.4% of the corresponding patient groups had an SF-36 PF ≥ 90, which is within normal range. In terms of worsening at six years, 5.9% of cyclophosphamide-treated, 10.3% of rituximab-, and 14.8% of placebo-treated patients had a drop in SF-36 PF of 20 points or more from baseline. There were no serious unexpected adverse reactions.

Conclusions

After six years, 44.1% of the cyclophosphamide group scored an SF-36 PF of at least 70, and 17.6% of at least 90, suggesting that cyclophosphamide in a subgroup may modulate the disease course in a beneficial way. However, cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials. Rather, these data should encourage efforts to better understand the disease mechanisms and to search for targeted and less toxic immune modulatory treatment for this patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabCyclophosphamideFatigue Syndrome, ChronicHumansFollow-Up StudiesFemaleMaleAdultMiddle AgedDouble-Blind MethodPatient Reported Outcome MeasuresTreatment Outcome

Substanzen

RituximabCyclophosphamide

Autor:innen und Institutionen

  • Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway.
  • Department of Clinical Sciences, University of Bergen, Bergen, Norway.
  • Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • KG Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, Norway.
  • Department of Biomedicine, University of Bergen, Bergen, Norway.

ORCID-Profile: Ingrid G Rekeland

Förderung

  • Norges Forskningsråd
  • Helse Vest
  • MEandYou Foundation
  • ME-foreningen
  • Kavlifondet
  • Helse- og Omsorgsdepartementet

Zitieren

APA

Rekeland, I. G., Sørland, K., Neteland, L. L., Fosså, A., Alme, K., Risa, K., Dahl, O., Tronstad, K. J., Mella, O., & Fluge, Ø. (2024). Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLOS ONE. https://doi.org/10.1371/journal.pone.0307484

Vancouver

Rekeland IG, Sørland K, Neteland LL, Fosså A, Alme K, Risa K, et al. Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. PLOS ONE. 2024. doi:10.1371/journal.pone.0307484

BibTeX
@article{Rekeland2024,
  author = {Rekeland, Ingrid G and Sørland, Kari and Neteland, Lisbeth Lykke and Fosså, Alexander and Alme, Kine and Risa, Kristin and Dahl, Olav and Tronstad, Karl J and Mella, Olav and Fluge, Øystein},
  title = {Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307484}
}
Kostenlos starten →